Researchers Find Eight New Unique Gene Mutations in Patients with Hereditable Heart Muscle Disease

Anderson Graphic

Intermountain Healthcare Heart Institute researchers have identified eight new gene mutations that may cause or contribute to idiopathic dilated cardiomyopathy.

If it’s passed on in families, we’ll be able to identify those who might be at risk for developing heart disease and work to prevent it, diagnose it, and begin treatment earlier.”

— Dr. Jeffrey Anderson, Intermountain Healthcare Heart Institute

SALT LAKE CITY , UT, USA , April 17, 2019 /EINPresswire.com/ — In a new study from the Intermountain Healthcare Heart Institute in Salt Lake City, researchers have identified eight new gene mutations that may cause or contribute to idiopathic dilated cardiomyopathy, a form of heart disease not caused by known external influences, such as high blood pressure, obesity, smoking, or diseased coronary arteries.

For at least 40 percent of these patients, the disease has an underlying genetic cause that leads to the muscle in the major pumping chamber of the heart (left ventricle) being too weak and thin to function properly, causing heart failure.

“Although many mutations contributing to non-ischemic dilated cardiomyopathy have been identified, there remains a large gap in our knowledge of its heritability. The more we can learn about what’s causing the condition, the better we can identify and treat it,” said Jeffrey L. Anderson, MD, principal investigator of the study, and a researcher at the Intermountain Healthcare Heart Institute. “If it’s passed on in families, we’ll be able to identify those who might be at risk for developing heart disease and work to prevent it, diagnose it, and begin treatment earlier.”

Findings from the study were presented at the American College of Cardiology’s Annual Scientific Session in New Orleans last month.

A quarter to one-third of idiopathic dilated cardiomyopathy patients will need a mechanical support device, a heart transplant, or will die within five years, Dr. Anderson noted, so this is a very serious condition.

In the study, researchers looked at genetic samples of 231 patients with idiopathic dilated cardiomyopathy, evaluated in an Intermountain Medical Center Specialty Clinic who volunteered to enter blood samples into the Intermountain Healthcare INSPIRE Registry and DNA Bank, which is the system’s collection of biological samples, clinical information, and laboratory data from consenting patients who are diagnosed with any of a number of healthcare-related conditions.

In collaboration with Intermountain’s Precision Genomics laboratory, researchers sequenced patients’ DNA, focusing on the TITIN (TNN) gene, which codes the body’s largest protein.

“That protein acts as a spring in your heart muscle,” said Dr. Anderson. “It enhances the passive elasticity of the muscle and also limits how much you can stretch it.”

Previous research has already found variants of TTN in patients with idiopathic dilated cardiomyopathy, but the story has been incomplete.

Now, in this new study, Intermountain researchers identified 24 patients with TTN variants, and eight of those variants hadn’t been seen or documented before. They also confirmed the presence of seven variants that had been discovered and reported previously. The new variants all are of the “truncating” variety, that is, they lead to a shortening of the protein and in doing so are predicted to cause the protein to malfunction in its role of maintaining the integrity of heart muscle function.

These new variants, Dr. Anderson said, still will require functional testing and clinical validation, but they likely will lead to further expansion of the known spectrum of genes that predispose to idiopathic dilated cardiomyopathy.

The addition of these variants to the current list of known pathological heart muscle protein mutations will help to close the still large gap in our knowledge of the heritability of heart muscle disease and in doing so can lead to earlier diagnosis and more effective prevention and treatment.

The study was funded by the Intermountain Foundation and an in-kind grant from Intermountain Precision Genomics.

Jess C. Gomez
Intermountain Healthcare
+1 801-718-8495
email us here


Source: EIN Presswire

Automobile High-strength Steel Market 2019 Global Trend, Segmentation And Opportunities Forecast To 2024

Automobile High-strength Steel -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

PUNE, MAHARASHTRA, INDIA, April 17, 2019 /EINPresswire.com/ — Automobile High-strength Steel Industry

Description

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Automobile High-strength Steel by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report. 

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.): 

Swedish Steel?SSAB? 
Nippon Steel & Sumitomo Metal 
ThyssenKrupp 
ArcelorMittal 
Baosteel Group 
Kobe Steel 
POSCO 
Ansteel 
BX STEEl 
Shougang Group

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3662562-global-automobile-high-strength-steel-market-analysis-2013

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.): 
Dual Phase Steels 
Complex Phase Steels 
Transformation Induced Plasticity Steels 
Martensitic Steels 
Quenching and Partitioning Steels 
Twinning Induced Plasticity Steels 
Press Hardening/Boron Steels  

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.): 
A Pillar 
B Pillar 
Reinforced Sill 
Roof Cross-Rail 
Longeron Assembles 
Door Panel 
Trunk Lid 
Others 

Region Coverage (Regional Production, Demand & Forecast by Countries etc.): 
North America (U.S., Canada, Mexico) 
Europe (Germany, U.K., France, Italy, Russia, Spain etc.) 
Asia-Pacific (China, India, Japan, Southeast Asia etc.) 
South America (Brazil, Argentina etc.) 
Middle East & Africa (Saudi Arabia, South Africa etc.)

Leave a Query @ https://www.wiseguyreports.com/enquiry/3662562-global-automobile-high-strength-steel-market-analysis-2013

Table of Content 

1 Industry Overview 
1.1 Automobile High-strength Steel Industry 
1.1.1 Overview 
1.1.2 Development of Automobile High-strength Steel 
1.2 Market Segment 
1.2.1 Upstream 
1.2.2 Downstream 
1.3 Cost Analysis 
2 Industry Environment 
2.1 Policy 
2.2 Economics 
2.3 Sociology 
2.4 Technology 
3 Automobile High-strength Steel Market by Type 
3.1 By Type 
3.1.1 Dual Phase Steels 
3.1.2 Complex Phase Steels 
3.1.3 Transformation Induced Plasticity Steels 
3.1.4 Martensitic Steels 
3.1.5 Quenching and Partitioning Steels 
3.1.6 Twinning Induced Plasticity Steels 
3.1.7 Press Hardening/Boron Steels 
3.2 Market Size 
3.3 Market Forecast 
4 Major Companies List 
4.1 Swedish Steel?SSAB? (Company Profile, Sales Data etc.) 
4.2 Nippon Steel & Sumitomo Metal (Company Profile, Sales Data etc.) 
4.3 ThyssenKrupp (Company Profile, Sales Data etc.) 
4.4 ArcelorMittal (Company Profile, Sales Data etc.) 
4.5 Baosteel Group (Company Profile, Sales Data etc.) 
4.6 Kobe Steel (Company Profile, Sales Data etc.) 
4.7 POSCO (Company Profile, Sales Data etc.) 
4.8 Ansteel (Company Profile, Sales Data etc.) 
4.9 BX STEEl (Company Profile, Sales Data etc.) 
4.10 Shougang Group (Company Profile, Sales Data etc.) 
5 Market Competition 
5.1 Company Competition 
5.2 Regional Market by Company 
6 Market Demand 
6.1 Demand Situation 
6.1.1 Demand in A Pillar 
6.1.2 Demand in B Pillar 
6.1.3 Demand in Reinforced Sill 
6.1.4 Demand in Roof Cross-Rail 
6.1.5 Demand in Longeron Assembles 
6.1.6 Demand in Door Panel 
6.1.7 Demand in Trunk Lid 
6.1.8 Demand in Others 
6.2 Regional Demand Comparison 
6.3 Demand Forecast 
7 Region Operation 
7.1 Regional Production 
7.2 Regional Market 
7.3 by Region 
7.3.1 North America 
7.3.1.1 Overview 
7.3.1.2 by Country (U.S., Canada, Mexico) 
7.3.2 Europe 
7.3.2.1 Overview 
7.3.2.2 by Country (Germany, U.K., France, Italy, Russia, Spain etc.) 
7.3.3 Asia-Pacific 
7.3.3.1 Overview 
7.3.3.2 by Country (China, India, Japan, Southeast Asia etc.) 
7.3.4 South America 
7.3.4.1 Overview 
7.3.4.2 by Country (Brazil, Argentina etc.) 
7.3.5 Middle East & Africa 
7.3.5.1 Overview 
7.3.5.2 by Country (Saudi Arabia, South Africa etc.) 
7.4 Regional Import & Export 
7.5 Regional Forecast 
8 Marketing & Price 
8.1 Price and Margin 
8.1.1 Price Trends 
8.1.2 Factors of Price Change 
8.1.3 Manufacturers Gross Margin Analysis 
8.2 Marketing Channel 
9 Research Conclusion

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3662562

Continued…                       

 

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Scientists crack the code to regenerate plant tissues

Tokyo University of Science

Tokyo University of Science

A group of scientists from TUS have discovered a way to regenerate flowering plant tissues, opening possibilities of mitigating global food shortage problem.

TOKYO, JAPAN, April 17, 2019 /EINPresswire.com/ — Plant regeneration can occur via formation of a mass of pluripotent cells. The process of acquisition of pluripotency involves silencing of genes to remove original tissue memory and priming for activation by external input. Led by Professor Sachihiro Matsunaga from Tokyo University of Science, a team of scientists have shown that plant regenerative capacity requires a certain demethylase that can prime gene expression in response to regenerative cues.

In multicellular organisms, not all genes are expressed in all cells, meaning that not all cells make the same enzymes or proteins, and therefore not all cells have the same metabolism. This differentiation is a key process across multicellular organisms, including plants and fungi. But as cells specialize, they become unipotent, meaning that they lose the ability to form multiple cell types. For long, scientists have tried to reprogram mammal cells for pluripotency by drastic means such as nuclear transfer and induction of transcription factors. However, plants can acquire the same regenerative powers via external signal input such as hormones and stress. A part of the phenomenon is regulated by epigenetics, because these modifications are epi or “above” the genes.

Professor Matsunaga and his team used Arabidopsis thaliana, a small flowering plant commonly used in plant biology, to study genome-wide histone modifications. Histones are proteins that package together eukaryotic DNA, preventing it from being transcribed or decoded. Upon being modified, however, these proteins’ grasp around the DNA molecule loosens, making it easier for the DNA to be transcribed. The group of scientists found that it is the demethylation (the removal of a methyl group from the amino acid) of the histone H3 by the LDL3 enzyme that lends regenerative competency to the plant. This epigenetic mechanism allows the plant’s pluripotent cells to go back to its unipotent state and thus assume the identity of shoot meristems for differentiated tissues including leaves and stems.

Because no seeds are needed to grow these plants, this could potentially help scientists grow plants faster without flowering. “By strengthening the ability of plants to reproduce, even without seeds,” Professor Matsunaga indicated, “it is possible to increase the number of clonal plants with only leaves, stems, and parts of roots. It can address environmental problems by promoting greening and solve the global food problem by increasing production of grains and vegetables.”

Reference
Title of original paper: Primed histone demethylation regulates shoot regenerative competency
Journal:
DOI: Nature Communications
https://doi.org/10.1038/s41467-019-09386-5

About the Tokyo University of Science
Tokyo University of Science (TUS) is one of the most well-known, respected, and the largest science-specialized private research university in Japan, with four campuses in central Tokyo and its suburbs and in Hokkaido. Established in 1881, the university has continually contributed to Japan's development in science through inculcating the love for science in researchers, technicians, and educators.

Tsutomu Shimizu
Tokyo University of Science
+81362612290
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Mizu, Innovative Bacteria Fighting Smart Towel Launches on eCommerce

Mizu Features 1

Discover Mizu. Everything you could ever dream of, all in one towel. You’ll wish you discovered it sooner.

Mizu Next Gen Towel

Discover the First Ever Smart Towel

Mizu Model

Smart. Comfortable. Stylish.

Mizu is the world’s first smart towel that tells you when it’s dirty via color changing stripes that sense impurities.

Mizu works on two fronts. 1) It eliminates bacterial growth and detects contaminants via a color-
changing stripe. 2) Pure, 100% silver is woven into cotton fibers of Mizu Towel”

— Mizu Towel

LOS ANGELES, CA, UNITED STATES, April 16, 2019 /EINPresswire.com/ — Mizu is the world’s first smart towel that tells you when it’s dirty. It has solvatochromic stripes that change color when they come into contact with impurities, so the user knows when to clean it. After months of development and testing by Cornell and MIT laureates, Mizu has launched on ecommerce to great success and steadily increasing demand. Mizu ships worldwide and is available for purchase at www.mizutowel.com.

Consumers and families are more hygiene-conscious then ever before, but many common household items are highly prone to bacterial growth. Mizu was engineered to offer both the luxurious comfort of a high-end towel and the technology to keep bathers cleaner and healthier.

“We are in the midst of a technological Renaissance,” said the founding team of Mizu, “and the middle class is growing worldwide. This means that many consumers across the globe care about hygiene more than, say, their parents or grandparents did, and these consumers are looking to technology to solve their problems. We saw a great opportunity here to create a product that was desirable and that had a positive impact.” Mizu is a modern solution that allows bathers to know, without a doubt, that they are clean after each bath or shower.

Mizu works on two fronts: it prevents bacterial growth and detects contaminants via a color-changing stripe (known as Mizutech). Pure 100% silver is woven into cotton fibers of the Mizu Towel. This all-natural element inhibits bacteria from growing and keeps the towel 99% free of disease-causing microbes. Other impurities like oil, dirt, sweat, and chemicals are detected by the patented Mizutech stripes. These color-changing indicators were developed by a team of textile engineering PhD holders and can only be found on Mizu Towels. When the color changes, it’s time for a wash.

Mizu is also one of the most comfortable towels on the market. It’s made from Xinjiang cotton, widely known as the softest cotton on Earth, and is constructed using Japanese techniques straight from Imabari. In the Towel industry, Imabari is a renowned region where royalty and the uber-elites go for their fabrics and custom clothing.

These Towels are also 50% larger and more absorbent than the average towel on the market. This increased volume allows the bather to dry off easier, rather than having to “scrub” with the towel. That generally means that Mizu stays cleaner for longer.

Mizu is made with safe and natural fibers that are suitable for all ages. Mizu hand and bath towels make brilliant additions to any living space but are also great for travelers and beach-goers who regularly come into contact with foreign contaminants. Thanks to Mizu’s twisted yarn weave, the textiles are incredibly durable and travel-friendly. They dry 3x faster than regular towels, making them ideal for trips to the pool or the gym.

About Mizu

Why do we get sick? Usually, it’s because we are exposed to harmful bacteria or toxins. While we try our best to stay clean, millions of contaminants and microscopic invaders thrive in places we least expect—our bedsheets, blankets, shoes, and towels. These are things we don’t clean enough because we don’t see the bacteria.

The founders of Mizu sought to make the world a cleaner place through a new line of smart fabrics that both resist contamination and also alert the user of when to wash. They successfully developed a prototype smart towel, but they knew that a smart towel alone would not be enough to succeed – they had to make a towel that people actually wanted to buy.

By sourcing the finest cotton and vigorous research, they discovered how to craft a towel that was truly comfortable (it’s not as easy as you think!). This led the Mizu team of doctors and engineers around the globe before they returned with the softest, most durable, and smartest towel on the planet.

Mizu is now shipping worldwide. For more information, visit www.mizutowel.com.

PR Team
Mizu Towel
+1 561-405-2663
email us here

Mizu Towel – Introducing the Smartest Towel Ever


Source: EIN Presswire

HOLY LAND MAN: 4 TYPES OF DEATHS ACCORDING TO THE BIBLE – life after death?

4 types of Biblical deaths according to HOLY LAND MAN

HOLY LAND MAN is Don Karl Juravin

HOLY LAND MAN

HOLY LAND MAN (Don Karl Juravin) researched the Bible in Hebrew to debate: What is death? Is there hell and heaven?

The study in the Hebrew Bible (original language) didn't find "hell" or "heaven" per the common belief. HOLY LAND MAN could not also find in the Bible a definite answer: is there life after death?”

— HOLY LAND MAN

ORLANDO, FLORIDA, UNITED STATES, April 16, 2019 /EINPresswire.com/ — Funerals can give us some of the most sobering moments of our lives, the purpose, meaning, and brevity of human existence coming out of the shadows and drawing into sharp focus. It’s only then, for a brief open-casket viewing, that we see our frailty and that our myopic tendencies are exposed for what they are: petty and trivial.

Could our refusal to talk about death actually be unbelief – doubting that heaven holds a better life for us than this one? Or is it simply a matter of an attention deficit – being captivated by motion and distracted by shiny objects that herd our thoughts toward temporary, fleeting, vanishing things?

>> HEAVEN IS NOT:

> Heaven isn’t now. Somewhere in the world, between twenty-five and thirty wars are being fought right now. Enough said.

> Heaven isn’t for everyone. Some people won’t be there. I know that sounds harsh and exclusive, but it’s the truth. We’ll get to this later.

> Heaven isn’t cute and ethereal. I’m not judging you if you have Precious Moments figurines on your bookshelf or mantle; I’m just saying heaven will not look like those. Nor will heaven look like what we see in cartoons or movies, where we float on clouds and God is Morgan Freeman.

> Heaven isn’t a state of mind or a mindless state. In some forms of Eastern thought, people aspire to be liberated from cravings, anger, and afflictive states. Nirvana is where there is nothing and where nothing is grasped. However, heaven is not nirvana.

>> HELL IS NOT

> Hell isn’t funny. Gary Larson’s Far Side comics are often hilarious, but what he depicts about heaven, and especially about hell, are just plain wrong. No one will ever laugh in hell.

> Hell isn’t a bearable annoyance. Often we are led to think that hell is just a bad hair day stretched out for a long time. Or something like this crosses our mind: My life is hell. Life can be difficult, but this life is not what the Bible describes as hell.

> Hell isn’t just for Hitler and those Columbine shooters and maybe a few more. Lost Springs, Wyoming, boasts a population of one. Jesus clearly indicated a population for hell that’s much greater than that of Lost Springs: “For wide is the gate and broad is the road that leads to destruction, and many enter through it” (Matthew 7:13, NIV).

Death means “separation.” What happens when a person dies? Now technically, the scriptures speak of at least four kinds of death in relation to one's spirit, soul and body:

1. SPIRITUAL DEATH (Isa.59:2; Eph. 2:1)

This death is the SEPARATION of man from God because of sin. Briefly explain the fall of Adam (Gen. 2:16-17). One can be alive physically but dead spiritually (Matt. 8:22; I Tim. 5:6). A lost person may have a live body, live soul, but dead spirit! The good news is that a sinner can still escape spiritual death and be spiritually resurrected (Eph. 2:5). A man has a lifetime of opportunity to escape spiritual death.

2. PHYSICAL DEATH (Jas. 2:26; Gen. 35:18)

This death is the SEPARATION of the INWARD man from OUTWARD man (cf. Eph. 3:16; II Cor. 4:16). There is no escape from physical death except at the Rapture! But barring the Rapture in our lifetime, we will all die and there is no escape in spite of the amazing advancements by technology, science, and medicine. Our BODY of flesh is the outward man that dies, corrupts and returns to dust (Job 34:15). On the other hand, the SOUL is the inward man that is immortal and incorruptible. The BODY may be dead but the SOUL is alive forevermore in heaven (II Cor.5:8) or hell (Luke 16:23). No soul sleep but body sleep instead!

One may be dead physically but that is not the end of everything (Heb. 9:27). The Bible teaches that the SOUL is ever alive and conscious even when the BODY is dead! We get a foretaste of physical death when we sleep and dream!

3. ETERNAL DEATH (Luke 16:19-21; Ezek. 18:4)

This is the SEPARATION of the SOUL from the BODY and SPIRIT to be cast into hell. When the BODY dies, it returns to dust and the SPIRIT returns to God who gave it (Eccl. 12:7). When the body dies, there is no more second chance of salvation for then the SOUL is lost and condemned forever and ever. It will be separated from God ETERNALLY! Unlike spiritual death, eternal death is irreversible!

4. SECOND or FINAL DEATH (Rev. 20:15; 21:8)

This will take place AFTER the Millennium at the Great White Throne Judgment. Contrary to popular belief, the Last Judgment does not occur at the Second Coming of Christ but only after His literal 1000-year earthly reign (Rev. 20:5-6). (Summarize passage). At the Last Judgment, the dead will be physically resurrected which means that their bodies will again re-unite with their souls to face God – the Judge and give an account. The sea, the grave, death, and hell itself will give up ALL the bodies and souls in them to be judged.

Notice that this second death is the casting of both BODY and SOUL into the Lake of Fire (Matt. 10:28). The Bible teaches TWO hells – one below the earth which is temporary (Matt. 12:40; Acts 2:27, 31) and the other above the earth which is everlasting – the Lake of Fire which was prepared for the devil and His angels (Matt. 25:41). Hell itself will be cast into the Lake of Fire (Rev. 20:14) along with those who will perish after the Last Judgment.

The final death results in the casting into the Lake of Fire of all the “rubbish of the universe” – Satan and his unholy angels, death, hell, sin, and sadly, all who died without repenting of their sins and rejected Christ as Lord & Saviour!

Conclusion: The Lake of Fire in its final state will be thick darkness (Jude 13), unquenchable fire, torment, suffering, plus worms (Mark 9:44-48). Friend, life is short, death is sure, sin is a curse but Christ is the hope and cure (John 11:25). Do you have 100% assurance of salvation in Christ?

DEATH AS "SLEEP"

The Bible compares death to sleep more than fifty times. After death we are asleep, we are unconscious; we are not aware of the passing of time or of what is going on around us. That is what death is like as well. The Bible says, “for the living know that they will die; but the dead know nothing… their love, their hatred, and their envy have now perished” (Ecclesiastes 9:5, NKJV, see also Psalm 146:4; 115:17).

It makes sense that after Lazarus was raised from the dead, he doesn’t share what he saw or experienced. He didn’t have anything to tell, except that once he was dead, and now he is alive! He didn’t experience hell or heaven. He was simply “sleeping” in his tomb. Peter on the Day of Pentecost said the same of King David. “Men and brethren, let me speak freely to you of the patriarch David, that he is both dead and buried, and his tomb is with us to this day…For David did not ascend into the heavens…"(Acts 2:29, 34).

WHAT CHRISTIANS BELIEVE ABOUT THE "SOUL"?

Many Christians think of the soul as an immortal entity within us that goes on living after death. What does the Bible say? Describing the creation of human beings in the beginning, the Bible says, “And the LORD God formed man of the dust of the ground, and breathed into his nostrils the breath of life; and man became a living soul” (Genesis 2:7, KJV). Other Bible translations say, “. . . and man became a living being” (NKJV; NIV). God did not put a soul into man.

He formed the body from the dust of the ground, and then He breathed His life-giving spirit into the lifeless body—and the result was a soul or a living being. When a person dies, the reverse takes place. The breath of life departs from the body, and the soul no longer exists. That’s what the Bible says. “The dust returns to the ground it came from, and the spirit returns to God who gave it” (Ecclesiastes 12:7, NIV). At the resurrection, God reunites the body and His life-giving spirit—and the person lives again.

If souls existed as separate entities that lived on after we died, that would mean we have immortality. However, the Bible says human beings do not have immortality. Only God is immortal (see 1 Timothy 6:15, 16). Paul says that the righteous “seek for glory, honor, and immortality” (Romans 2:7). If we had immortal souls, why would the righteous seek after something they already have?

SCRIPTURES

Maybe simply defined as the termination of life. It is represented under a variety of aspects in Scripture:

> "The dust shall return to the earth as it was" (Eccl 12:7).

> "Thou takest away their breath, they die" (Psalms 104:29).

> It is the dissolution of "our earthly house of this tabernacle" (2Corinthians 5:1); the "putting off this tabernacle" (2 Peter 1:132 Peter 1:14).

> Being "unclothed" (2 Corinthians 5:3 2 Corinthians 5:4).

> "Falling on sleep" (Psalms 76:5 ; Jeremiah 51:39 ; Acts 13:36 ; 2 Pet 3:9)

> "I go whence I shall not return" (Job 10:21); "Make me to know mine end" (Psalms 39:4); "to depart" (Phil 1:23).

> The grave is represented as "the gates of death" (Job 38:17 ; Psalms 9:13 ; 107:18). The gloomy silence of the grave is spoken of under the figure of the "shadow of death" (Jeremiah 2:6 ). Death is the effect of sin (Hebrews 2:14), and not a "debt of nature." It is but once (9:27), universal (Genesis 3:19), necessary (Luke 2:28-30). Jesus has by his own death taken away its sting for all his followers (1 Corinthians 15:55-57).

> There is spiritual death in trespasses and sins, i.e., the death of the soul under the power of sin ( Romans 8:6 ; Ephesians 2:1Ephesians 2:3 ; Colossians 2:13 ).

> The "second death" (Revelation 2:11) is the everlasting perdition of the wicked (Revelation 21:8), and "second" in respect to natural or temporal death.

Research by: Don Karl Juravin (USA)

Credit and sources:

https://Juravin.com
https://twitter.com/DonJuravin
https://www.facebook.com/Juravin
https://www.linkedin.com/in/juravin/
https://www.linkedin.com/company/juravin
https://www.pinterest.com/Juravin
https://www.instagram.com/juravin/
https://www.youtube.com/Juravin
https://juravin.tumblr.com/
https://www.tumblr.com/blog/juravin
https://www.reddit.com/user/Juravin
https://plus.google.com/+DonJuravin

PR
https://hype.news/don-juravin
https://www.openpr.com/news/archive/215186/Don-Juravin.html
http://www.einpresswire.com/newsroom/juravin/

Research
https://juravin.academia.edu/
https://zenodo.org/record/2551844#.XGiJWM9Kh24
http://scholar.google.com/citations?user=jCdHy0EAAAAJ&hl=en
https://researchgate.net/profile/Don_Juravin
https://orcid.org/0000-0002-7537-2939

Blog Contributor
https://juravin.wordpress.com
https://medium.com/@Juravin
https://juravin.quora.com
https://hype.news/don-juravin
https://juravin.blogspot.com/

Docs
https://www.scribd.com/user/377772125/Don-Karl-Juravin

Local
https://juravin.business.site

Profile
https://www.ted.com/profiles/7929318

Don Karl Juravin
HOLY LAND MAN
+1 813-922-5888
email us here

God has three answers for us


Source: EIN Presswire

Save the date for SMi’s 10th Annual Biosimilars Conference 2019

P-298 Biosimilars 2019

SMi Group are pleased to announce the 10th Biosimilars Conference, the first global show taking place at Copthorne Tara Hotel London on 25th and 26th September.

LONDON, LONDON, UNITED KINGDOM, April 16, 2019 /EINPresswire.com/ — The biosimilars market is forecasted to reach USD$23.6B by 2023 at a compound annual growth rate (CAGR) of 31.70%. Factors driving the increase of this market include growing demand for biosimilar drugs due to their cost-effectiveness, growing incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

With the expiry dates of major patents fast approaching, the emerging gap in the market for biosimilars is now a major attraction for manufacturers. As the availability of biosimilars could potentially reduce direct spending by USD$54B by 2026, the two-day event aims to tackle the question “What can current biosimilar producing companies do to join this market to benefit the patients, physicians and investors?”

The 2019 event focus is to highlight the current challenges in the biosimilars market and discuss current undergoing plans or developments to overcome these challenges, with carefully hand-picked keynote addresses and case studies presented by top manufacturing and leading distributors of market approved biosimilars including:

Bristows LLP will talk about current strategies under development to overcome challenges with patents currently faced by many biosimilar developers.
MHRA will discuss the possible changes in regulatory approval of biosimilars in the UK post Brexit, and how this will impact market entry.
Bio-thera Solutions is set to explore the commercialization uptake in the China market.
Novartis will review the recently approved drug delivery systems for biosimilars.

The event brochure with the full agenda and speaker line-up is available now. Download the brochure at http://www.biosimilars-europe.com/pr1

The conference is chaired by Michel Mikhail, International Expert in Regulatory Affairs, International Expert in Biosimilars, Independant Consultant.

Speakers confirmed so far include:
• Anne Cook, Biologicals Quality Assessor, Medicines & Healthcare Products Regulatory Agency
• Dan Cohen, Regional Senior European Director Biosimilars, Biogen
• louis Boon, CSO, Bioceros
• Steiner Madsen, Medical Director, Norwegian Medicines Agency
• Aurelio Arias, Senior Thought Leadership Consultant, IQVIA

Plus, there are two interactive half-day pre-conference workshops on Tuesday 24th September:
Workshop A is led by Michel Mikhail, International Expert Regulatory Affairs, Global Expert of Biosimilars on the topic of ‘US-FDA Interchangeability Guideline’.
Workshop B is led by Rodeina Challand, General Manager, Challand Biosimilar Consulting on the topic of ‘Global Development of Biosimilars – what can the US learn from Europe’s Strategies to promote biosimilar uptake’.

Take advantage of the biggest early bird discount of £400 expiring on Tuesday 30 April 2019. Register at http://www.biosimilars-europe.com/pr1

For sponsorship enquires, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk

SMi’s 10th Annual Biosimilars Conference
Conference: 25-26 September 2019
Workshops: 24 September 2019
Copthorne Tara Hotel, London, UK
http://www.biosimilars-europe.com/pr1
#SMiBiosimilars

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
+1 2078276000
email us here


Source: EIN Presswire

High Content Screening/Imaging Market By Global Manufacturers, Regions, Type And Application, Forecast To 2024

High Content Screening/Imaging -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

PUNE, MAHARASHTRA, INDIA, April 16, 2019 /EINPresswire.com/ — High Content Screening/Imaging Industry

Description

Wiseguyreports.Com Adds “High Content Screening/Imaging -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database

High content screening (HCS) is a technique that has been developed to collect quantitative data from cell populations. The market is growing at a CAGR of REDACTED and is expected to reach REDACTED in 2023, up from REDACTED in 2017. HCS systems allow relatively high throughput screening of cells, in which each cell in an array would be analyzed at a subcellular resolution using multicolored, fluorescence-based reagents for both specificity and sensitivity. The method is integrated with analytical tools such asmicroscopy, multiparameter image processing, and visualization tools. HCS integrates the instrumentation, application software, reagents, sample preparation, and informatics and bioinformatics required to rapidly flow from producing data, generating information, and ultimately creating new cellular knowledge. High content screening is increasingly being adopted in biological research and drug discovery. Additionally, it is being implemented in oncology, neuroscience, and oncology research, including primary compound screening and post-primary screening. Recently, high content approaches have been used extensively in stem cell biology.

The major factors contributing to the growth of the HCS market is the rising adoption of high content screening technology in research and development activities. The rapid adoption of HCS technology in the pharmaceutical industry and academic research center indicates the importance of this informationrich screening tool. The imaging of cell function has become increasingly important to understand the underlying functional biology associated with new therapeutic targets. Demand for improved technologies for cell research, government support and emergence of sophisticated informatics solutions, and rising demand for better screening systems is augmenting the demand for high content imaging within fully automated screening laboratories. Furthermore, technological advancements and developments in biological research and the discovery of more effective therapies for the treatment of human disease is fueling the growth of the market.

HCS imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of assays involving complex cellular disease models. Increasing drug discovery R&D globally, increasing investments and introduction of advanced imaging instruments are the other drivers for the HCS market.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3493834-high-content-screening-imaging-technologies-and-global-markets

The high cost of HCS instrumentation is the primary factor restraining the growth of the market. The price of machinery and instrumentation prohibits a small economy country or a research organization from purchasing HCS equipment. Companies are introducing more sensitive cameras and better light sources such as LED and multicolor illumination, which are increasing the output and reliability of the system and, therefore, the overall cost of the microscopes. The price of HCS equipment varies from a hundred thousand to a million, depending on the specifications. Inadequate infrastructure and less funding for R&D in emerging countries will also hinder the market as installation and maintenance costs
are also very high and not easily feasible for emerging economies.

Adoption of HCS in the analysis of 3D spheroids, microtissues and phenotypic assays, are expected to impact gene editing studies based on CRISPR-Cas9 in the future. Moreover, the growing availability of perturbagen libraries and HCS infrastructure within academic research centers has prompted widespread interest in HCS applications among academic investigators.

The combination of HCS with chemical genetics, where small organic molecules are used to study biological systems has emerged as a powerful approach for defining protein functions and dissecting signaling pathways. The rapid growth of genome-wide RNA interference (RNAi) technology to probe gene function in mammalian cell culture systematically have popularized HCS systems in academic research environments.

Leave a Query @ https://www.wiseguyreports.com/enquiry/3493834-high-content-screening-imaging-technologies-and-global-markets

Report Scope

The HCS/I market has significant potential due to rising demand from the drug discovery and molecular diagnosis segments. The capabilities and possibilities of HCS/I market growth increases with the growth of new technologies and technological advancements. Emerging economies such as China, India, and South Korea are considered to be lucrative regions that are creating ample opportunities and scope for the market. Investments and funding from government and private ventures, research institutes and universities are supporting exploration into the potential of this market. Growing drug discovery and molecular diagnostic and research through HCS/I will further boost the market in the near future. The global rise in infectious and noninfectious diseases, growing populations, technological advancements and innovation are other factors creating considerable demand for HCS/I.

The scope of this study encompasses the current market for drug discovery, molecular diagnostics, cancer research, personalized medicine and compound profiling. The report also includes regulatory aspects, recent developments, market projections, competitive landscapes and market share. Analyses of patents, clinical trials, innovations and opportunities, as well as the latest trends, are also discussed in the report. The report intends to explain the key trends of HCS/I technologies and applications in various geographies. It also discusses the market determinants that act as motivating and restraining factors and provides insights to stakeholders and potential entrants. The report will be a key decision-making tool for government organizations, researchers, private players, angel investors, potential entrants and so forth.

Report Includes:

– 38 data tables and 23 additional tables
– An overview of the global markets for high content screening/imaging technologies
– Analyses of global market trends, with data from 2017, estimated from 2018 and projections of compound annual growth rates (CAGRs) through 2023
– Coverage of various microscope and imaging technologies in the industry
– Detailed analysis of the technological advancement in cytometers, light sources, detectors/sensors and liquid handling instruments
– Discussion of the various market motivators i.e. increasing R&D budget, advantages over manual and HTS, technological advancement, and automation
– Company profiles of major players in the industry, including Albany Molecular Research, Inc. (AMRI), Cell Signaling Technology, Danaher Corp., GE Healthcare and Instrument Systems

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3493834

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Positive results of regional perfusion chemotherapy for progressive and refractory ovarian cancer made public today

Scheme of Isolated Hypoxic Abdominal Perfusion with Chemofiltration (HAP-F)

Scheme of Isolated Hypoxic Abdominal Perfusion with Chemofiltration (HAP-F)

Hypoxic abdominal perfusion for progressive and refractory ovarian cancer is an effective therapy offering comparably long survival at good quality of life

BURGHAUSEN, GERMANY, April 16, 2019 /EINPresswire.com/ — Medias Klinikum GmbH & Co KG, a private hospital specialized in surgical oncology, focusing on the treatment of primary and metastatic solid tumors, announces the publication of an observational cohort study of 45 patients entitled Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients in the peer-reviewed Indian Journal of Surgical Oncology (DOI: https://doi.org/10.1007/s13193-019-00922-9), that was conducted by Professor Dr. Karl R. Aigner, one of the world’s most experienced experts in the field of regional chemotherapy, and his group. In 1981, he developed the technique of isolated liver perfusion and was the first physician worldwide performing this method in humans using a heart-lung machine.

Commenting on the announcement, Professor Dr. Karl R. Aigner, Head of the Department of Surgical Oncology at Medias Klinikum, said, “Ovarian cancer is the leading cause of death among all gynecological cancers. The standard therapy option is still complete cytoreduction when possible, combined with chemotherapy. Despite initial response rates of 70–80% to platinum-based combination chemotherapies with taxanes, platinum-resistant recurrences occur very frequently within 2 years. The shorter the recurrence-free interval, the lower the prospect of a renewed response to chemotherapy. While increased drug exposure could theoretically lead to a renewed response, they are not universally administered due to increased toxicity. The limiting factor of augmented systemic drug exposure always had been the increasing toxicity such as neuropathy with hand–foot syndrome, neutropenia, or fatigue to the point of exhaustion. Since mortality rates of ovarian cancer remain high and have hardly changed in the last three decades, more recent treatment options are being tested in the context of molecular biology research.”

He adds: “Prolonging life while maintaining or improving quality of life should be the basic requirement for any cancer treatment. No other fundamental necessity for any treatment to be recommended should actually apply. In a comparative study, we therefore looked at patients who were in progression following systemic chemotherapy and were then treated with regional chemotherapy. The main endpoint of the trial was quality of life, overall survival, and clinical response rates:

Complete or partial response on clinical symptoms was noted among 36.3% of all patients in stages IIIB/C and IV. Stable disease was achieved in 51.1% of patients. Complete disappearance of ascites was observed in 30% of patients after only two perfusions; 43% of patients reported a substantial reduction of abdominal pressure and fluid volume and a considerable improvement in general wellbeing. Profit in terms of high response rates was achieved by increased tumor toxicity of the anticancer drugs under hypoxic conditions. Due to subsequent chemofiltration, systemic drug exposure was reduced and toxic side effects kept low. Quality of life generally was reported undisturbed.”

The method of regional chemotherapy in terms of isolated hypoxic abdominal perfusion with chemofiltration (HAP-F) for multiply pre-treated patients with progressive and platinum-refractory stage III and IV ovarian cancer, in fact is an effective therapy that can break through chemoresistance and offering comparably long survival at good quality of life.

This initial data have been supplemented by further results obtained with a larger number of patients and presented during an oral presentation at the this year’s 14th International Symposium on Regional Cancer Therapies of the Society of Surgical Oncology (SSO) in Phoenix, AZ, USA.

The updated data will be sent for publication within the next month.

About Medias Klinikum, Department of Surgical Oncology
Medias Klinikum is a private clinic located in Burghausen (Bavaria), Germany specialized in regional chemotherapy (RCT), a targeted treatment modality for primary and metastatic tumors that generates high locoregional drug exposure and is less toxic. Looking back at 40 years of expertise in this special field of surgical oncology, Prof. Dr. med. Aigner, the medical director of the clinic, is one of the world’s most experienced experts in this treatment method. He has given numerous lectures on RCT or performed guest operations in the most renowned institutions in the USA, Japan, China, Israel, Egypt, Australia and a number of other countries. In 1981, Professor Aigner developed a technique for performing the first isolated liver perfusion in humans using a heart-lung machine, and over subsequent years a variety of additional surgical procedures and specialized catheters for isolated therapy of organs and parts of the body, including the treatment of pancreatic carcinoma.

Public Relations
Medias Klinikum GmbH & Co KG
+49 8677 91600
email us here
Visit us on social media:
Facebook
Google+


Source: EIN Presswire

“The Importance of Getting your Children Vaccinated”, new article by Pediatrician Dr. Kenneth Rebong

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong Profile on MedicoGazette

Dr Kenneth Rebong Profile on MedicoGazette

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Office of Dr Kenneth Rebong, San Jose, CA

Office of Dr Kenneth Rebong, San Jose, CA

Kenneth Rebong, MD, doctor in California

Kenneth Rebong, MD, doctor in California

It’s important to get children vaccinated as soon as they are born. This will keep them safe from a plethora of deadly diseases, explains Dr. Kenneth Rebong.

Kenneth Pomar Rebong, MD (N/A:N/A)

Presumably all parents want to keep their children safe. That includes the necessary medical care and vaccinations.”

— Dr. Kenneth P Rebong, pediatrician

SAN JOSE, CALIFORNIA, UNITED STATES, April 16, 2019 /EINPresswire.com/ — It’s important to get children vaccinated to keep them safe from a plethora of potentially deadly diseases. But as always, when in doubt, review the issues with the pediatrician based on the medical history. Presumably all parents want to keep their children safe. That includes the necessary medical care and vaccinations. However, there are controversial and contradictory opinions and information about vaccinations for children. Dr. Kenneth Rebong, MD, based in San Jose, California, provides his thoughts on this issue. The complete article is available on the Blog of Dr. Rebong at https://drkennethrebong.wordpress.com/

Let us start with the basics: What Is a Vaccine?

By now, you probably understand why people are vaccinated. Let’s talk about vaccines in layman terms. A vaccine is a product that is given to children, as well as adults, to protect them from infectious diseases. There are various types of vaccines and every year, developments are made to counteract the effects of new diseases discovered. The chemical components in a vaccine stimulate production of antibodies and provide immunity against various disease processes.

Now here’s the truly fascinating part: the vaccine works due to the causative agent present in the disease, which is used as a synthetic substitute. The antigen induces an immune response in the body without injecting the disease.

So here are the Top 5 Reasons to Get Your Child Vaccinated (and remember that when you are unsure, the child’s pediatrician, based on the available medical history, probably knows best):

1.Get Your Child Vaccinated (usually within first 12 Months) to protect against some diseases

The first vaccination is usually given to a child within the first 12 months (this may differ depending on the particular case, again consult the pediatrician). The basic MMR vaccine protects infants from rubella, measles, and mumps. Another important vaccine that should be given at 2 months is IPV, which protects newborn babies from polio.

Vaccines are given from birth to 18 years. You can check out the schedules and recommended doses at the Centers for Disease Control and Prevention or check with the pediatrician.

2. Vaccines Provide a Shield Against Serious Illnesses

If your child does not get vaccinated at the right time, his or her immune system becomes vulnerable to attacks. When you travel with your children abroad, not only are they at risk but they also put other children at risk.

Some of the vaccine-preventable diseases are:
* Diphtheria
* Hepatitis A
* Haemophilus influenza type b (Caused by bacterial meningitis)
* Hepatitis B
* Influenza
* Human Papillomavirus (Caused by of cervical cancer)
* Measles
* Mumps
* Meningococcal
* Pertussis (Whooping Cough)
* Polio
* Pneumococcal (Causes blood infections and bacterial meningitis)
* Rotavirus
* Tetanus (Lockjaw)
* Rubella (German measles)
* Varicella (Chickenpox)

These diseases can lead to serious complications such as amputation of leg or arm, paralysis of limbs, brain damage, convulsions, and even death.

3. Vaccines Protect Your Child’s Future

Children are exposed to germs on a daily basis. Following are some of the places where your child is likely to come into contact with dangerous bacteria:

* Preschool or daycare
* School
* College
* University
* Doctor’s waiting room
* Community center
* Events and concerts
* Summer camp
* An airplane or a bus

These germs spread through crowded places and by the time you notice the symptoms starting to appear, it may be too late.

4. Vaccines Are Generally Safe

Side effects from vaccines are rarely seen. Consult with your health care professional for more details.

5. Vaccines Save You from Expensive Medical Bills

https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html, which you can refer to, to find out how much your insurance will cover. Remember: get your children vaccinated as their future is at stake here.

About Dr. Kenneth P Rebong

Dr. Kenneth Pomar Rebong, MD, a medical doctor in San Jose, California, and specializes in Pediatrics and Adolescent Medicine. He completed his Pediatric Residency at RUTGERS University in New Brunswick, New Jersey.

https://medicogazette.com/dr-kenneth-pomar-rebong
https://hippocratesguild.com/dr-kenneth-pomar-rebong
https://www.linkedin.com/in/kenneth-pomar-rebong-md-4484a938/

Kenneth Pomar Rebong, MD
Kenneth Pomar Rebong, MD
+1 408-729-3232
email us here
Visit us on social media:
LinkedIn

Will Trump empower vaccine-sceptic parents? BBC News


Source: EIN Presswire

Is it Hemp – Is it Marijuana- Is it Recreational – Is it Medical – What is it all about?

Testing forTHC,CBD, CBG ,CBN in cannabis products

Testing cannabinoids in Hemp and Cannabis products and plant material

THC, CBD testing charts

Potency and finger print charts

Cannabis-Hemp  Certified test kits, complete  mini lab

Complete mini lab all you need to strat a small TLC lab includes 80-100 test

You need to know what is Hemp in order to Benefit your Life and your Wallet

MEFORD, OR, U.S.A., April 16, 2019 /EINPresswire.com/ — Let’s start with, what is it Marijuana or Hemp? well the current USA laws would like you to believe that Hemp is NOT a type of Marijuana plant but instead an industrial, medical farm plant that before this year was as federally illegal as a THC based Marijuana plant which is still a federally illegal narcotic, Class 1. Now the federal government has decided that a Hemp plant is a legal Farm Crop and is no longer part of any type of drug laws and is now equal to farming a potato, managed by the FDA NOT the DEA.

The reality is that Hemp is Marijuana with a lot less THC originally produced in the plant were” Marijuana” has normally a lot more natural THC which to this date is the only cannabinoid illegal in Marijuana, and also the only one presently known that can give psycho-active results, like eating the wrong type of mushroom were psilocybin is the psycho active ingredient in some but not others.

There are at least 40-70 protentional medical cannabinoids in a marijuana plant and around 140 cannabinoids all together in one plant, so which plant will come out as the leader, I believe neither. They are both the same DNA structure and even the DEA cannot come up with a filed test to tell the difference between a Marijuana plant and a Hemp plant, so the logical conclusion will be that both will become seen as one (for many different reasons) so laws can become consistent throughout the USA at some point.

Benefits of both plants:

Hemp Plants is a marijuana plant that naturally produces a very small amount of THC, since the plant creates its own balance of cannabinoids, if you have a higher CBD content then you will have a lower THC content in the plant, so for CBD product producers and manufactures starting with a plant that has very little THC is a big + Since most states currently require less than 1% THC in any CBD products currently produced. The seeds from the plant are crushed along with any tri-cones that can be harvested from the plant and the oils used for everything form medicines to hand creams with a lot more in between.

The Hemp plant was grown by the US government for years to produce clothing but mostly for making large ropes that ships used to tie down to harbor docks and was grown until the early 60’s when polyester rope was created and replaced all the commercial rope products. Currently the CBD medicines are proving to be real health aids.

We at TLC Lab Supply have been selling TLC testing kits and supplies for over 10 years and the feedback from the CBD and THC products that are tested with our kits has been consistent and always show very positive results for the clients and producers we hear from. The amount of CBD in a product varies there are no standards for any CBD products other than no THC (in them which is in my opinion in some medicines is needed in conjunction with the CBD but that is another topic). But testing your products to determine potency and consistent results will be the bases for many products, we supply those testing products with our kits if you have less than 1% THC you will get a blank spot were the THC marker would be seen.

Marijuana Plants

To start with, this plant cannot make up its mind if it is a girl or a boy until over ½ way through its growing period ( how many plants do you know that work like that) that is one of the reasons that clones ( from a female cannabis plant) were created to insure that you get an already started female plant rather than start with a seed, which with a normal seed, you would have to wait weeks to determine if it was a female which is what people that want high THC will need. Normally you will also know what type of plant you are going to have (Indica or Sativa) and that it will be a girl.

Fact: TESTING OF ANY CANNABIS PRODUCTS IS A MUST!

All states and most legal countries require testing to determine either the high THC content for consistent results of THC based products or for legal CBD products you must have less the 1% THC to be a legal CBD product so you must test to make sure you have less the 1% and you must also test for the potency of THC and CBD in all cannabis products. There are labs, all with Gas Chromatography (GC), Liquid Chromatography (HPLC) (which have no legal testing standards because the federal government has not created any yet) and Thin Layer Chromatography, (TLC). These are the 3 most common used testing methods for cannabis (go here for independent study of all 3 types of testing)- https://www.thctestkits.com/3labtesting/).

Current California testing laws suggest using TLC testing for most of their products.

TLC Lab Supply has been selling Certified THC, CBD, CBG and CBN testing kits and supplies for testing cannabis plant material and products made from plant material from Marijuana and Hemp worldwide. They give consistent results and accuracy, are very easy to use and extremely affordable. For a ton of information, an instructional video and our online store go to: https://www.thctestkits.com/

Hemp based products are currently on retail shelfs in Hawaii and are advertised to be in CVS and Walgreens Pharmacy, soon they will be everywhere, if you are a product producer or in the cannabis industry you will need to be ready for a great opportunity to get your products on the retail shelves of many different types of outlets in the next year. So be ready, test your products for accuracy in potency and consistency for your product production.

Roger Green
R Green Services/ TLC Lab Supply
5416901000
email us here
Visit us on social media:
Facebook
Twitter
Google+
LinkedIn

Instructional video using our testing kits – easy to use, consistent results


Source: EIN Presswire